Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Seminars in Oncology Nursing|February 25, 2014
Methodological considerations in the design and implementation of clinical trialsConstance T Cirrincione, Ellen M Lavoie Smith, Herbert PangJournal of the American College of Surgeons|January 17, 2017
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)David W Ollila, Constance T Cirrincione, Donald A Berry, et al.Journal of Geriatric Oncology|December 14, 2017
The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436)Vicki A Morrison, Linda McCall, Hyman B Muss, et al.Annals of Surgery|July 30, 2015
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group BRaymond B Weiss, Susan H Woolf, Erin Demakos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907Stuart M Lichtman, Constance T Cirrincione, Arti Hurria, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)Harold J Burstein, Constance T Cirrincione, William T Barry, et al.Archives of Pathology & Laboratory Medicine|April 27, 2018
Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host DiseaseDiana M Cardona, Claire J Detweiler, Michael J Shealy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343Kevin S Hughes, Lauren A Schnaper, Jennifer R Bellon, et al.Breast Cancer Research and Treatment|October 6, 2016
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.Pageof 3